HRP20200853T1 - Pripravci namijenjeni upotrebi u postupcima liječenja rana, poremećaja, te bolesti kože - Google Patents
Pripravci namijenjeni upotrebi u postupcima liječenja rana, poremećaja, te bolesti kože Download PDFInfo
- Publication number
- HRP20200853T1 HRP20200853T1 HRP20200853TT HRP20200853T HRP20200853T1 HR P20200853 T1 HRP20200853 T1 HR P20200853T1 HR P20200853T T HRP20200853T T HR P20200853TT HR P20200853 T HRP20200853 T HR P20200853T HR P20200853 T1 HRP20200853 T1 HR P20200853T1
- Authority
- HR
- Croatia
- Prior art keywords
- pharmaceutical preparation
- herpes simplex
- simplex virus
- preparation according
- genome
- Prior art date
Links
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims 5
- 208000035475 disorder Diseases 0.000 title claims 3
- 206010052428 Wound Diseases 0.000 title claims 2
- 208000027418 Wounds and injury Diseases 0.000 title claims 2
- 201000010099 disease Diseases 0.000 title claims 2
- 238000000034 method Methods 0.000 title claims 2
- 239000000203 mixture Substances 0.000 title 1
- 241000700584 Simplexvirus Species 0.000 claims 12
- 239000000825 pharmaceutical preparation Substances 0.000 claims 10
- 229920001184 polypeptide Polymers 0.000 claims 5
- 108090000765 processed proteins & peptides Proteins 0.000 claims 5
- 102000004196 processed proteins & peptides Human genes 0.000 claims 5
- 206010014989 Epidermolysis bullosa Diseases 0.000 claims 3
- 108700005077 Viral Genes Proteins 0.000 claims 3
- 230000000415 inactivating effect Effects 0.000 claims 3
- 230000035772 mutation Effects 0.000 claims 3
- 208000017520 skin disease Diseases 0.000 claims 3
- 102000004510 Collagen Type VII Human genes 0.000 claims 2
- 108010017377 Collagen Type VII Proteins 0.000 claims 2
- 201000004624 Dermatitis Diseases 0.000 claims 2
- 101150027427 ICP4 gene Proteins 0.000 claims 2
- 108700019146 Transgenes Proteins 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- 238000002347 injection Methods 0.000 claims 2
- 239000007924 injection Substances 0.000 claims 2
- 108090000623 proteins and genes Proteins 0.000 claims 2
- 238000010254 subcutaneous injection Methods 0.000 claims 2
- 239000007929 subcutaneous injection Substances 0.000 claims 2
- 102000008490 2-Oxoglutarate 5-Dioxygenase Procollagen-Lysine Human genes 0.000 claims 1
- 108010020504 2-Oxoglutarate 5-Dioxygenase Procollagen-Lysine Proteins 0.000 claims 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
- 201000004625 Acrodermatitis Diseases 0.000 claims 1
- 206010007882 Cellulitis Diseases 0.000 claims 1
- 201000000297 Erysipelas Diseases 0.000 claims 1
- 101100181372 Homo sapiens LAMB3 gene Proteins 0.000 claims 1
- 241000700588 Human alphaherpesvirus 1 Species 0.000 claims 1
- 101001042049 Human herpesvirus 1 (strain 17) Transcriptional regulator ICP22 Proteins 0.000 claims 1
- 101000999690 Human herpesvirus 2 (strain HG52) E3 ubiquitin ligase ICP22 Proteins 0.000 claims 1
- 101150090364 ICP0 gene Proteins 0.000 claims 1
- 108700002232 Immediate-Early Genes Proteins 0.000 claims 1
- 206010021531 Impetigo Diseases 0.000 claims 1
- 108010076876 Keratins Proteins 0.000 claims 1
- 102000011782 Keratins Human genes 0.000 claims 1
- 101150063253 LAMB3 gene Proteins 0.000 claims 1
- 208000011219 Netherton syndrome Diseases 0.000 claims 1
- 206010034277 Pemphigoid Diseases 0.000 claims 1
- 208000004210 Pressure Ulcer Diseases 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 claims 1
- 241001303601 Rosacea Species 0.000 claims 1
- 208000000453 Skin Neoplasms Diseases 0.000 claims 1
- 206010041955 Stasis dermatitis Diseases 0.000 claims 1
- 101150044021 UL41 gene Proteins 0.000 claims 1
- 101150081415 UL55 gene Proteins 0.000 claims 1
- 201000006083 Xeroderma Pigmentosum Diseases 0.000 claims 1
- 208000010668 atopic eczema Diseases 0.000 claims 1
- 201000000751 autosomal recessive congenital ichthyosis Diseases 0.000 claims 1
- 208000005035 cutaneous candidiasis Diseases 0.000 claims 1
- 230000003436 cytoskeletal effect Effects 0.000 claims 1
- 201000001981 dermatomyositis Diseases 0.000 claims 1
- 208000007150 epidermolysis bullosa simplex Diseases 0.000 claims 1
- 101150029683 gB gene Proteins 0.000 claims 1
- 201000002597 ichthyosis vulgaris Diseases 0.000 claims 1
- 201000011486 lichen planus Diseases 0.000 claims 1
- 206010025135 lupus erythematosus Diseases 0.000 claims 1
- 101710130522 mRNA export factor Proteins 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000008363 phosphate buffer Substances 0.000 claims 1
- 230000000069 prophylactic effect Effects 0.000 claims 1
- 201000004700 rosacea Diseases 0.000 claims 1
- 201000000849 skin cancer Diseases 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
- 238000011200 topical administration Methods 0.000 claims 1
- 230000000699 topical effect Effects 0.000 claims 1
- 231100000331 toxic Toxicity 0.000 claims 1
- 230000002588 toxic effect Effects 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
- A61K35/763—Herpes virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- A61K38/1748—Keratin; Cytokeratin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/44—Oxidoreductases (1)
- A61K38/443—Oxidoreductases (1) acting on CH-OH groups as donors, e.g. glucose oxidase, lactate dehydrogenase (1.1)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/16—Emollients or protectives, e.g. against radiation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/0004—Oxidoreductases (1.)
- C12N9/0071—Oxidoreductases (1.) acting on paired donors with incorporation of molecular oxygen (1.14)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y114/00—Oxidoreductases acting on paired donors, with incorporation or reduction of molecular oxygen (1.14)
- C12Y114/11—Oxidoreductases acting on paired donors, with incorporation or reduction of molecular oxygen (1.14) with 2-oxoglutarate as one donor, and incorporation of one atom each of oxygen into both donors (1.14.11)
- C12Y114/11004—Procollagen-lysine 5-dioxygenase (1.14.11.4), i.e. lysine-hydroxylase
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
- C12N2710/16641—Use of virus, viral particle or viral elements as a vector
- C12N2710/16643—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Epidemiology (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Molecular Biology (AREA)
- Wood Science & Technology (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Dermatology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- Virology (AREA)
- Toxicology (AREA)
- Biophysics (AREA)
- Marine Sciences & Fisheries (AREA)
- Mycology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
Claims (14)
1. Farmaceutski pripravak, naznačen time što sadrži:
a) replikacijski defektan virus herpes simplex (HSV), koji sadrži genom rekombinantnog virusa herpes simplex, gdje genom rekombinantnog virusa herpes simplex sadrži jedan ili više transgena koji kodiraju polipeptid kojeg se bira iz skupine koju čine polipeptid kolagenskog α-1 (VII) lanca, polipeptid lizil-hidroksilaze 3 i citoskeletni polipeptid 17 keratinskog tipa I; i
b) farmaceutski prihvatljivi nosač,
gdje genom rekombinantnog virusa herpes simplex has been engineered to decrease ili eliminate eksprimiranje jednog ili više toksičnih gena virusa HSV.
2. Farmaceutski pripravak u skladu s bilo kojim od patentnim zahtjevom 1, naznačen time što je virus herpes simplex (HSV) virus herpes simplex tip 1.
3. Farmaceutski pripravak u skladu s bilo kojim od patentnog zahtjeva 1 ili patentnim zahtjevom 2, naznačen time što genom rekombinantnog virusa herpes simplex sadrži inaktivirajuću mutaciju.
4. Farmaceutski pripravak u skladu s patentnim zahtjevom 3, naznačen time što je inaktivirajuća mutacija u jednom ili više neposrednih ranih gena virusa HSV.
5. Farmaceutski pripravak u skladu s patentnim zahtjevom 3, naznačen time što je inaktivirajuća mutacija u najmanje jednom genu virusa herpes simplex kojeg se bira iz skupine koju čine ICP0, ICP4, ICP22, ICP27, ICP47, tk, UL41, te UL55.
6. Farmaceutski pripravak u skladu s bilo kojim od patentnih zahtjeva 1-5, naznačen time što genom rekombinantnog virusa herpes simplex sadrži jedan ili više transgena u jednom ili više virusnih genskih lokusa, te što jedan ili više virusnih genskih lokusa mogu biti jedan ili više od lokusa virusnog gena ICP4.
7. Farmaceutski pripravak u skladu s bilo kojim od patentnih zahtjeva 1-6, naznačen time što je farmaceutski prihvatljivi nosač pogodan za topikalnu primjenu, transdermalnu primjenu, supkutanu injekciju, intradermalnu injekciju, transmukozalnu primjenu ili bilo koje njihove kombinacije.
8. Farmaceutski pripravak u skladu s bilo kojim od patentnih zahtjeva 1-7, naznačen time što je slijed polipeptid kolagenskog α-1 (VII) lanca najmanje 80% istovjetan slijedu iz SEQ ID NO: 2.
9. Farmaceutski pripravak u skladu s bilo kojim od patentnih zahtjeva 1-8, naznačen time što farmaceutski prihvatljivi nosač sadrži fosfatni pufer.
10. Farmaceutski pripravak u skladu s bilo kojim od patentnih zahtjeva 1-9, naznačen time što je namijenjen upotrebi u postupku pružanja profilaktičnog, palijativnog ili terapijskog ublažavanja rane, poremećaja ili bolesti kože kod subjekta.
11. Pripravak namijenjen upotrebi u skladu s patentnim zahtjevom 10, naznačen time što je farmaceutski pripravak pogodan za topikalnu primjenu, transdermalnu primjenu, supkutanu injekciju, intradermalnu injekciju, transmukozalnu primjenu ili bilo koja njihovu kombinaciju na subjektu.
12. Pripravak namijenjen upotrebi u skladu s bilo kojim od patentnog zahtjeva 10 ili patentnog zahtjeva 11, naznačen time što je bolest ili poremećaj kože jedno ili više od bulozne epidermolize, raka kože, psorijaze, lihen planusa, lupusa, rozaceje, egzema, kutane kandidijaze, celulitisa, impetiga, dekubitalnih ulkusa, erizipela, obične ihtioze, dermatomiozitisa, akrodermatitisa, stazisnog dermatitisa, Nethertonovog sindroma, jednostavne bulozne epidermolize (gen LAMB3), autosomne recesivne kongenitalne ihtioze, pigmentne kseroderme, te pemfigoida.
13. Pripravak namijenjen upotrebi u skladu s patentnim zahtjevom 10 ili patentnim zahtjevom 11, naznačen time što je bolest ili poremećaj kože bulozna epidermoliza (EB).
14. Pripravak namijenjen upotrebi u skladu s bilo kojim od patentnih zahtjeva 10-13, naznačen time što je subjekt čovjek.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662320316P | 2016-04-08 | 2016-04-08 | |
PCT/US2016/068974 WO2017176336A1 (en) | 2016-04-08 | 2016-12-28 | Compositions and methods for the treatment of wounds, disorders, and diseases of the skin |
EP16826873.8A EP3377637B1 (en) | 2016-04-08 | 2016-12-28 | Compositions for use in methods for the treatment of wounds, disorders, and diseases of the skin |
Publications (1)
Publication Number | Publication Date |
---|---|
HRP20200853T1 true HRP20200853T1 (hr) | 2020-08-21 |
Family
ID=57822104
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HRP20200853TT HRP20200853T1 (hr) | 2016-04-08 | 2020-05-27 | Pripravci namijenjeni upotrebi u postupcima liječenja rana, poremećaja, te bolesti kože |
Country Status (21)
Country | Link |
---|---|
US (7) | US9877990B2 (hr) |
EP (2) | EP3377637B1 (hr) |
JP (3) | JP6970086B2 (hr) |
KR (1) | KR20180128016A (hr) |
CN (1) | CN109072255A (hr) |
AU (3) | AU2016401692B2 (hr) |
CA (1) | CA3017487A1 (hr) |
CL (3) | CL2018002814A1 (hr) |
CY (1) | CY1123024T1 (hr) |
DK (1) | DK3377637T3 (hr) |
ES (1) | ES2796488T3 (hr) |
HR (1) | HRP20200853T1 (hr) |
HU (1) | HUE049237T2 (hr) |
LT (1) | LT3377637T (hr) |
MX (2) | MX2018012135A (hr) |
PL (1) | PL3377637T3 (hr) |
PT (1) | PT3377637T (hr) |
RS (1) | RS60410B1 (hr) |
SG (1) | SG11201808314QA (hr) |
SI (1) | SI3377637T1 (hr) |
WO (1) | WO2017176336A1 (hr) |
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BR112017013858A2 (pt) | 2014-12-26 | 2018-02-27 | Univ Emory | n4-hidroxicitidina e derivados e usos antivirais relacionados aos mesmos |
JP6970086B2 (ja) | 2016-04-08 | 2021-11-24 | クリスタル バイオテック,インコーポレイティド | 皮膚の創傷、障害、及び疾患を処置するための組成物及び方法 |
CN110312506A (zh) * | 2016-11-14 | 2019-10-08 | 密歇根大学董事会 | 用于阻挡紫外线辐射的组合物和方法 |
CA3049652A1 (en) | 2017-01-10 | 2018-07-19 | Intrexon Corporation | Modulating expression of polypeptides via new gene switch expression systems |
MX2020005392A (es) | 2017-12-07 | 2020-12-07 | Univ Emory | N4-hidroxicitidina y derivados y usos antivirales relacionados con los mismos. |
CA3094345A1 (en) | 2018-04-12 | 2019-10-17 | Krystal Biotech, Inc. | Compositions and methods for the treatment of autosomal recessive congenital ichthyosis |
WO2019210219A1 (en) | 2018-04-27 | 2019-10-31 | Krystal Biotech, Inc. | Recombinant nucleic acids encoding cosmetic protein(s) for aesthetic applications |
CA3112627A1 (en) | 2018-09-24 | 2020-04-02 | Krystal Biotech, Inc. | Compositions and methods for the treatment of netherton syndrome |
CA3112633A1 (en) | 2018-09-26 | 2020-04-02 | Krystal Biotech, Inc. | Compositions and methods for the treatment of skin diseases |
WO2020149395A1 (ja) * | 2019-01-18 | 2020-07-23 | 国立大学法人大阪大学 | 栄養障害型表皮水疱症治療薬 |
US10829529B2 (en) | 2019-02-08 | 2020-11-10 | Krystal Biotech, Inc. | Compositions and methods for delivering CFTR polypeptides |
EP3946596A4 (en) * | 2019-03-27 | 2022-12-21 | Phoenix Tissue Repair, Inc. | SYSTEMS AND METHODS OF PRODUCING COLLAGEN COMPOSITIONS 7 |
EP4025699A1 (en) | 2019-09-03 | 2022-07-13 | Krystal Biotech, Inc. | Compositions and methods for the treatment of congenital ichthyoses |
CN112724225B (zh) * | 2019-10-28 | 2023-09-26 | 中国医学科学院药物研究所 | 一种角蛋白bd-6、制法和其药物组合物与用途 |
EP4077688A1 (en) | 2019-12-20 | 2022-10-26 | Krystal Biotech, Inc. | Compositions and methods for gene delivery to the airways and/or lungs |
CN117412986A (zh) | 2021-04-02 | 2024-01-16 | 克里斯托生物技术股份有限公司 | 用于癌症疗法的病毒载体 |
WO2023064806A1 (en) | 2021-10-12 | 2023-04-20 | Phoenix Tissue Repair, Inc. | Collagen 7 protein replacement therapy |
CN117143223B (zh) * | 2022-08-23 | 2024-03-08 | 山西锦波生物医药股份有限公司 | 一种生物合成人体结构性材料的制备方法 |
Family Cites Families (39)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5672344A (en) * | 1987-12-30 | 1997-09-30 | The Regents Of The University Of Michigan | Viral-mediated gene transfer system |
US5658724A (en) | 1992-07-31 | 1997-08-19 | University Of Pittsburgh Of The Commonwealth System Of Higher Education | Herpes simplex virus strains deficient for the essential immediate early genes ICP4 and ICP27 and methods for their production, growth and use |
IL132087A0 (en) * | 1997-04-10 | 2001-03-19 | Univ Southern California | Modified proteins which bind extracellular matrix components |
US5998174A (en) | 1997-05-12 | 1999-12-07 | University Of Pittsburgh Of The Commonwealth System Of Higher Education | Multigene vectors |
GB9715085D0 (en) * | 1997-07-18 | 1997-09-24 | Jahoda Amanda J | Gene therapy vehicle |
US6106826A (en) * | 1997-12-17 | 2000-08-22 | Wisconsin Alumni Research Foundation | Replication competent, avirulent Herpes simplex virus as a vector for neural and ocular gene therapy |
GB9801930D0 (en) * | 1998-01-29 | 1998-03-25 | Univ London | Mutant herpes simplex viruses and uses thereof |
WO1999064094A1 (en) * | 1998-06-12 | 1999-12-16 | Aradigm Corporation | Methods of delivering aerosolized polynucleotides to the respiratory tract |
JP2003535565A (ja) | 1998-12-31 | 2003-12-02 | アーチ ディベロプメント コーポレイション | 新生物疾患の治療に有用な組換え単純ヘルペスウイルス |
GB9930418D0 (en) * | 1999-12-22 | 2000-02-16 | Neurovex Ltd | Replication incompetent herpes virus vectors |
AU1788502A (en) * | 2000-11-28 | 2002-06-11 | Univ Chicago | Genetically engineered herpes virus for the treatment of cardiovascular disease |
AU2003298786A1 (en) | 2002-11-26 | 2004-06-18 | Protein Design Labs, Inc. | Methods of detecting soft tissue sarcoma, compositions and methods of screening for soft tissue sarcoma modulators |
CN101203530A (zh) * | 2004-10-28 | 2008-06-18 | 匹兹堡大学高等教育联邦体系 | 关于脊髓损伤疼痛的外周递送的谷氨酸脱羧酶基因治疗 |
RU2007131689A (ru) * | 2005-01-21 | 2009-02-27 | Интроджен Тетрапьютикс, Инк. (Us) | Местное введение терапевтических и профилактических нуклеиновых кислот, обеспечивающее их пролонгированное действие на клетки-мишени |
AU2006252406B2 (en) * | 2005-06-01 | 2012-05-17 | California Institute Of Technology | Method of targeted gene delivery using viral vectors |
US8703703B2 (en) * | 2006-12-20 | 2014-04-22 | University Of Central Flordia Research Foundation, Inc. | MCPIP as wound therapy |
WO2008106646A2 (en) * | 2007-03-01 | 2008-09-04 | Introgen Therapeutics, Inc | Methods and formulations for topical gene therapy |
US20080289058A1 (en) * | 2007-05-14 | 2008-11-20 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Targeted delivery of glycine receptors to excitable cells |
WO2009105690A2 (en) * | 2008-02-21 | 2009-08-27 | Targeted Genetics Corporation | Devices and methods for delivering polynucleotides into retinal cells of the macula and fovea |
CN102212559B (zh) | 2011-04-14 | 2014-04-09 | 郑州威瑞生物技术有限公司 | 一种重组的hsv扩增子载体及其用途 |
US9340783B2 (en) * | 2011-10-11 | 2016-05-17 | Inserm (Institut National De La Sante Et De La Recherche Medicale | Exon skipping therapy for dystrophic epidermolysis bullosa |
GB201202561D0 (en) | 2012-02-15 | 2012-03-28 | Univ Dundee | Treatment of skin disorders |
CN104768567B (zh) * | 2012-05-18 | 2017-07-11 | 奥塔哥创业有限公司 | 用于伤口愈合的联合治疗和组合物 |
AU2014223243B2 (en) * | 2013-03-01 | 2019-10-17 | Regents Of The University Of Minnesota | Talen-based gene correction |
BR112015022868B1 (pt) * | 2013-03-14 | 2023-05-16 | Ethris Gmbh | Composições de mrna de cftr e usos e métodos relacionados |
WO2015009952A1 (en) * | 2013-07-17 | 2015-01-22 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Non-toxic hsv vectors for efficient gene delivery applications and complementing cells for their production |
ES2810800T3 (es) * | 2013-10-28 | 2021-03-09 | Univ Pittsburgh Commonwealth Sys Higher Education | Vector de HSV oncolítico |
MX2016009771A (es) | 2014-01-31 | 2016-11-14 | Factor Bioscience Inc | Metodos y productos para la produccion y administracion de acido nucleico. |
GB2526339A (en) * | 2014-05-21 | 2015-11-25 | Imp Innovations Ltd | Lentiviral vectors |
WO2016049183A1 (en) * | 2014-09-24 | 2016-03-31 | Aerpio Therapeutics, Inc. | Ve-ptp extracellular domain antibodies delivered by a gene therapy vector |
JP6925805B2 (ja) * | 2014-10-31 | 2021-08-25 | 京都府公立大学法人 | ラミニンによる角膜の新規治療 |
US20180148711A1 (en) * | 2015-05-28 | 2018-05-31 | Coda Biotherapeutics, Inc. | Genome editing vectors |
CN109069668B (zh) * | 2015-12-14 | 2023-04-18 | 宾夕法尼亚州大学信托人 | 用于眼病的基因疗法 |
EP3432905B1 (en) * | 2016-03-25 | 2022-06-01 | PeriphaGen, Inc. | Hsv vectors for delivery of nt3 and treatment of cipn |
DK3432912T3 (da) * | 2016-03-25 | 2023-03-13 | Periphagen Inc | Hsv-vektorer med høj transduktion |
JP6970086B2 (ja) | 2016-04-08 | 2021-11-24 | クリスタル バイオテック,インコーポレイティド | 皮膚の創傷、障害、及び疾患を処置するための組成物及び方法 |
CA3094345A1 (en) | 2018-04-12 | 2019-10-17 | Krystal Biotech, Inc. | Compositions and methods for the treatment of autosomal recessive congenital ichthyosis |
WO2019210219A1 (en) | 2018-04-27 | 2019-10-31 | Krystal Biotech, Inc. | Recombinant nucleic acids encoding cosmetic protein(s) for aesthetic applications |
JP2021529531A (ja) | 2018-06-29 | 2021-11-04 | クリスタル バイオテック インコーポレイテッド | 抗体送達のための組成物及び方法 |
-
2016
- 2016-12-28 JP JP2018521309A patent/JP6970086B2/ja active Active
- 2016-12-28 CA CA3017487A patent/CA3017487A1/en active Pending
- 2016-12-28 PT PT168268738T patent/PT3377637T/pt unknown
- 2016-12-28 DK DK16826873.8T patent/DK3377637T3/da active
- 2016-12-28 EP EP16826873.8A patent/EP3377637B1/en active Active
- 2016-12-28 LT LTEP16826873.8T patent/LT3377637T/lt unknown
- 2016-12-28 CN CN201680084419.7A patent/CN109072255A/zh active Pending
- 2016-12-28 RS RS20200669A patent/RS60410B1/sr unknown
- 2016-12-28 PL PL16826873T patent/PL3377637T3/pl unknown
- 2016-12-28 KR KR1020187030112A patent/KR20180128016A/ko not_active Application Discontinuation
- 2016-12-28 US US15/393,151 patent/US9877990B2/en active Active
- 2016-12-28 MX MX2018012135A patent/MX2018012135A/es unknown
- 2016-12-28 EP EP20161137.3A patent/EP3712273A1/en active Pending
- 2016-12-28 WO PCT/US2016/068974 patent/WO2017176336A1/en active Application Filing
- 2016-12-28 HU HUE16826873A patent/HUE049237T2/hu unknown
- 2016-12-28 AU AU2016401692A patent/AU2016401692B2/en active Active
- 2016-12-28 SG SG11201808314QA patent/SG11201808314QA/en unknown
- 2016-12-28 SI SI201630776T patent/SI3377637T1/sl unknown
- 2016-12-28 ES ES16826873T patent/ES2796488T3/es active Active
-
2017
- 2017-12-21 US US15/851,488 patent/US10155016B2/en active Active
-
2018
- 2018-10-03 CL CL2018002814A patent/CL2018002814A1/es unknown
- 2018-10-04 MX MX2022006072A patent/MX2022006072A/es unknown
- 2018-10-31 US US16/177,153 patent/US10441614B2/en active Active
-
2019
- 2019-10-10 US US16/598,982 patent/US11185564B2/en active Active
- 2019-12-13 AU AU2019280069A patent/AU2019280069B2/en active Active
-
2020
- 2020-05-27 HR HRP20200853TT patent/HRP20200853T1/hr unknown
- 2020-06-05 CY CY20201100503T patent/CY1123024T1/el unknown
-
2021
- 2021-04-09 CL CL2021000881A patent/CL2021000881A1/es unknown
- 2021-10-27 JP JP2021175260A patent/JP7480105B2/ja active Active
- 2021-11-17 US US17/529,161 patent/US20220273737A1/en not_active Abandoned
-
2022
- 2022-06-30 AU AU2022204729A patent/AU2022204729A1/en active Pending
- 2022-11-30 US US18/060,515 patent/US11865148B2/en active Active
-
2023
- 2023-03-15 CL CL2023000743A patent/CL2023000743A1/es unknown
- 2023-06-27 US US18/342,284 patent/US20230414686A1/en active Pending
- 2023-07-04 JP JP2023109819A patent/JP2023118838A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20200853T1 (hr) | Pripravci namijenjeni upotrebi u postupcima liječenja rana, poremećaja, te bolesti kože | |
JP2019513689A5 (hr) | ||
JP2022023174A5 (hr) | ||
Lieberman | Epigenetics and genetics of viral latency | |
Knipe et al. | Chromatin control of herpes simplex virus lytic and latent infection | |
JP2022023099A (ja) | 単純ヘルペス1型および他の関連するヘルペスウイルスのrnaガイド除去 | |
Castañeda et al. | piRNAs, transposon silencing, and germline genome integrity | |
He et al. | Sequence analysis of the complete genome of an iridovirus isolated from the tiger frog | |
Werden et al. | Poxvirus host range genes | |
Kanai et al. | Effect of γ34. 5 deletions on oncolytic herpes simplex virus activity in brain tumors | |
Parkinson | Do telomerase antagonists represent a novel anti-cancer strategy? | |
Deng et al. | Telomeres and viruses: common themes of genome maintenance | |
ES2627103T3 (es) | Composiciones de cuidado bucal y métodos | |
WO2006018632A2 (en) | Cell therapy with exo 1 | |
Gennart et al. | Marek's disease: Genetic regulation of gallid herpesvirus 2 infection and latency | |
Mejías-Pérez et al. | Development of a safe and effective vaccinia virus oncolytic vector WR-Δ4 with a set of gene deletions on several viral pathways | |
KR20120095450A (ko) | 단순 헤르페스 바이러스 백신 | |
Wayengera | Identity of zinc finger nucleases with specificity to herpes simplex virus type II genomic DNA: novel HSV-2 vaccine/therapy precursors | |
Hicks et al. | Current state of Marek's disease virus microRNA research | |
Kang et al. | Establishment and maintenance of HSV latent infection is mediated through correct splicing of the LAT primary transcript | |
ES2233349T3 (es) | Reordenacion por promotores especificos para una celula y/o especificos para un tumor de la expresion del gen gamma 34,5 herpetico. | |
Klein | Initiation and maintenance of latent herpes simplex virus infections: the paradox of perpetual immobility and continuous movement | |
WO2011126856A3 (en) | Herpes simplex virus mutant icp0 | |
Spencer et al. | 340. Development of a Nuclease Screen to Improve Cas9 Targeting Specificity | |
Black et al. | A single viral gene determines lethal cross-species neurovirulence of baboon herpesvirus HVP2 |